Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.

Abstract

Selective cyclooxygenase-2 (COX-2) inhibitors have anti-inflammatory activity and reduce proteinuria in experimental membranous glomerulonephritis. Antiangiogenic properties of COX-2 inhibitors were recently reported. Whether these properties are relevant to the glomerular healing process in inflammatory glomerular diseases was investigated. For evaluation of the effects of selective COX-2 inhibitors on the glomerular healing process in a rat model of mesangioproliferative glomerulonephritis (induced by anti-Thy 1.1 antibody), a selective COX-2 inhibitor (rofecoxib or celecoxib) or vehicle was administered daily from day 1 after disease induction until euthanasia on day 6. Additional nephritic rats were treated with rofecoxib or vehicle from day 1 to day 10 and were monitored until day 28. Selective COX-2 inhibition led to significant increases in mesangiolysis (up to +71%) on days 2 and 6 and in albuminuria (up to 3.1-fold) on day 6. This augmentation of glomerular capillary damage was associated with rarefaction of glomerular endothelial cells, whereas the proliferation and activation of mesangial cells were not affected. No significant effects on the glomerular influx of polymorphonuclear neutrophils or the infiltration and proliferation of monocytes/macrophages at day 2 were noted. These effects were independent of systemic hemodynamic features, because rofecoxib did not affect systolic BP on day 2 or 5. Nephritic rats treated with rofecoxib for 10 d demonstrated persistent glomerular injury at day 28, as indicated by increased albuminuria (10-fold) and mesangial type IV collagen deposition (+24%). In normal rats, 5-d administration of rofecoxib failed to induce albuminuria or morphologic renal damage. In conclusion, selective COX-2 inhibitors impair glomerular capillary repair after mesangiolysis in rats with anti-Thy 1.1 glomerulonephritis. These data suggest that selective COX-2 inhibitors should be used with caution among patients with inflammatory endocapillary glomerular disorders.

• Authors: Masashi Kitahara, Frank Eitner, Tammo Ostendorf, Uta Kunter, Ulf Janssen, Ralf Westenfeld, Katsuyuki Matsui, Dontscho Kerjaschki, Jürgen Floege
• Journal: Journal of the American Society of Nephrology : JASN (J Am Soc Nephrol) Vol. 13 Issue 5 Pg. 1261-1270 (May 2002) ISSN: 1046-6673 [Print] United States
• PMID: 11961014 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclooxygenase Inhibitors
• Lactones
• Pyrazoles
• Sulfonamides
• Sulfones
• rofecoxib
• Celecoxib

Topics

• Animals
• Celecoxib
• Cyclooxygenase Inhibitors (pharmacology, toxicity)
• Glomerular Mesangium (blood supply, drug effects, metabolism)
• Glomerulonephritis, Membranoproliferative (metabolism, physiopathology)
• Hemodynamics (drug effects)
• Immunoenzyme Techniques
• Lactones (pharmacology, toxicity)
• Microscopy, Electron
• Pyrazoles
• Rats
• Statistics, Nonparametric
• Sulfonamides (pharmacology, toxicity)
• Sulfones